RBOT

• Stephen From has been focused on achieving design freeze of the production-equivalent system by year-end 2026, and reducing burn by evaluating outsourcing opportunities and structural changes, including restructuring internal teams and reducing headcount. - Engaged PA Consulting to perform a gap analysis and prepare recommendations and request for proposals for outsourcing partners, expected to be completed by end of November. - Strengthened balance sheet with approximately $5.9 million in gross proceeds from a registered direct offering in October. - Plan to share updates about platform development on LinkedIn page and Investor Relations website for transparency, including progress and challenges. - Sarah Romano presented financials showing total operating expenses, R&D, G&A, sales and marketing expenses decreases, and cash position.

• Continue to expect full year 2025 cash burn to be approximately $50 million and actively focused on reducing 2026 cash burn. - Confident in driving material reduction in cash burn going forward and actively exploring further opportunities to bolster balance sheet. - Target design freeze of production-equivalent system by year-end 2026.

Total operating expenses for the third quarter 2025 were $11.5 million, a 35% decrease compared to $17.8 million in the third quarter of 2024. Research and development expenses for the third quarter 2025 were $8 million compared to $10.8 million in the third quarter of 2024. General and administrative expenses for the third quarter '25 were $3.2 million compared to $5.7 million in the third quarter 2024. Sales and marketing expenses for the third quarter 2025 were $350,000 compared to $1.2 million in the third quarter of '24. GAAP net loss for the third quarter of 2025 was $11.1 million or $1.86 per share, compared to GAAP net loss of $17.1 million or $2.90 per share in the third quarter of '24. Non-GAAP adjusted net loss for the third quarter of 2025 was $11.3 million or adjusted net loss of $1.91 per share compared to $17 million or $2.87 per share in the third quarter of '24. Ended the third quarter 2025 with approximately $13.4 million of cash, cash equivalents and short-term investments, with a third quarter cash burn rate of approximately $10.5 million.

• Forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. - Risks and uncertainties associated with business set forth in SEC filings, including most recent Form 10-K and Form 10-Q. - Outsourcing initiative may bring some disruption which could potentially affect timelines if not managed properly.

Q: Just wanted to confirm or correct the timeline for system build to regulatory testing and clinical use and how outsourcing impacts that?

A: Still looking to have design freeze towards end of 2026. Although outsourcing may cause some disruption, hoping it doesn't affect timeline too much and will communicate disruptions timely. Outsourcing is in early stages with PA Consulting engaged.

Q: Can provide additional color on development builds, like cadaver labs and internal testing?

A: Have own OR, surgeons come in to test systems. Had a surgeon perform IPOM surgery for first time, saw dramatic drop in suturing time from 40 minutes to 14 minutes showing improvement in system stability and reliability.

Q: How long do you anticipate the consulting engagement to take? And what is the cost? And what are you doing to solve preserving cash while reaching design freeze at year-end 2026?

A: PA Consulting engagement is short, to go through analysis for outsourcing. Cost is fixed fee. Did a small layoff (about 15% of employees) to control burn and went through exercise to determine who to lay off.

Q: Where do you stand with your hospital and health system partners through all of this?

A: Have ongoing communications, relationships are strong. Surgeons from hospitals come to play with systems, get feedback, and are excited. For example, a surgeon never seen the system before was able to perform an IPOM surgery here.